Huang Xishun, Luo Meixuan, Zeng YanYan, Yi Jiao, Lin Sumei, Wang Yitao, Zheng Xuan, Luo Xiaohua
Department of health medicine, The 909th Hospital, School of Medicine, Xiamen University, Zhangzhou, Fujian, PR China.
Department of oncology, The 909th Hospital, School of Medicine, Xiamen University, Zhangzhou, Fujian, PR China.
Am J Med Sci. 2025 Mar;369(3):373-379. doi: 10.1016/j.amjms.2024.10.005. Epub 2024 Oct 23.
Non-alcoholic fatty liver disease is a liver condition that is increasing globally. Unfortunately, there are no successful or approved pharmacological treatments for non-alcoholic fatty liver disease. Hence, this study aimed to investigate the effect of therapeutic lifestyle changes on patients with overweight/obesity and non-alcoholic fatty liver disease.
A prospective, parallel-group, randomized controlled trial was conducted. The patients were randomized into intervention and control groups using tables with random numbers. In the control group, routine health guidance was provided for 3 months, while in the intervention group, diversified lifestyle intervention was provided. The body composition, visceral fat area, abdominal circumference, and body mass index of the control and intervention groups were compared before and after the intervention. Descriptive statistics, paired t-tests, and linear regression models were used for data analysis.
A total of 115 participants (57 in the intervention group and 58 in the control group) completed the study. The intervention groups had significantly greater high-density lipoprotein cholesterol levels, basal metabolic rate, muscle mass, and questionnaire scores than the control groups (P < 0.05). Furthermore, the intervention participants had lower body mass index, abdominal circumference, triglyceride levels, low-density lipoprotein cholesterol levels, and fatty liver index (P < 0.05).
Therapeutic lifestyle changes therapy for non-alcoholic fatty liver disease patients with overweight/obesity can significantly control body mass index, improve blood lipid levels, reduce fatty liver and body fat rates, improve basic metabolism, alleviate disease, and improve quality of life. More research is needed to determine the long-term impact of therapeutic lifestyle changes in high-risk groups.
非酒精性脂肪性肝病是一种在全球范围内日益增多的肝脏疾病。不幸的是，目前尚无成功或获批的非酒精性脂肪性肝病药物治疗方法。因此，本研究旨在探讨治疗性生活方式改变对超重/肥胖合并非酒精性脂肪性肝病患者的影响。
进行了一项前瞻性、平行组、随机对照试验。使用随机数字表将患者随机分为干预组和对照组。对照组接受为期3个月的常规健康指导，而干预组则接受多样化的生活方式干预。比较干预前后对照组和干预组的身体成分、内脏脂肪面积、腹围和体重指数。采用描述性统计、配对t检验和线性回归模型进行数据分析。
共有115名参与者（干预组57名，对照组58名）完成了研究。干预组的高密度脂蛋白胆固醇水平、基础代谢率、肌肉量和问卷得分显著高于对照组（P<0.05）。此外，干预组参与者的体重指数、腹围、甘油三酯水平、低密度脂蛋白胆固醇水平和脂肪肝指数较低（P<0.05）。
对超重/肥胖的非酒精性脂肪性肝病患者进行治疗性生活方式改变疗法可显著控制体重指数，改善血脂水平，降低脂肪肝和体脂率，提高基础代谢，缓解疾病，并改善生活质量。需要更多研究来确定治疗性生活方式改变对高危人群的长期影响。
